@article{WittbrodtLammersMalitscheketal.1992,
  author    = {Wittbrodt, Joachim and Lammers, Reiner and Malitschek, Barbara and Ullrich, Axel and Schartl, Manfred},
  title     = {Xmrk receptor tyrosine kinase is activated in Xiphophorus malignant melanoma},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-61699},
  year      = {1992},
  abstract  = {Xmrk encodes a putative transmembrane glycoprotein of the tyrosine kinase family and is a melanoma-inducing gene in Xiphophorus. We attempted to investigate the biological function of the putative Xmrk receptor by characterizing its signalling properties. Since a potential Iigand for Xmrk has not yet been identified, it has been difficult to analyse the biochemical properlies and biological function of this cell surface protein. In an approach towards such analyses, the Xmrk extracellular domain was replaced by the closely related Iigand-binding domain sequences of the human epidennal growth factor receptor (HER) and the ligand-induced activity of the chimeric HER-Xmrk proteinwas examined. We show that the Xmrk protein is a functional receptor tyrosine kinase, is highly active in malignant melanoma and displays a constitutive autophosphorylation activity possibly due to an activating mutation in its extracellular or transmembrane domain. In the focus formation assay the HER-Xmrk chimera is a potent transfonning protein equivalent to other tyrosine kinase oncoproteins.},
  subject      = {Physiologische Chemie},
  language  = {en}
}
@article{WendlingerWohlfarthKreftetal.2022,
  author    = {Wendlinger, Simone and Wohlfarth, Jonas and Kreft, Sophia and Siedel, Claudia and Kilian, Teresa and Dischinger, Ulrich and Heppt, Markus V. and Wistuba-Hamprecht, Kilian and Meier, Friedegund and Goebeler, Matthias and Schadendorf, Dirk and Gesierich, Anja and Kosnopfel, Corinna and Schilling, Bastian},
  title     = {Blood eosinophils are associated with efficacy of targeted therapy in patients with advanced melanoma},
  series = {Cancers},
  volume    = {14},
  journal   = {Cancers},
  number    = {9},
  issn      = {2072-6694},
  doi       = {10.3390/cancers14092294},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-275137},
  year      = {2022},
  abstract  = {Background: Eosinophils appear to contribute to the efficacy of immunotherapy and their frequency was suggested as a predictive biomarker. Whether this observation could be transferred to patients treated with targeted therapy remains unknown. Methods: Blood and serum samples of healthy controls and 216 patients with advanced melanoma were prospectively and retrospectively collected. Freshly isolated eosinophils were phenotypically characterized by flow cytometry and co-cultured in vitro with melanoma cells to assess cytotoxicity. Soluble serum markers and peripheral blood counts were used for correlative studies. Results: Eosinophil-mediated cytotoxicity towards melanoma cells, as well as phenotypic characteristics, were similar when comparing healthy donors and patients. However, high relative pre-treatment eosinophil counts were significantly associated with response to MAPKi (p = 0.013). Eosinophil-mediated cytotoxicity towards melanoma cells is dose-dependent and requires proximity of eosinophils and their target in vitro. Treatment with targeted therapy in the presence of eosinophils results in an additive tumoricidal effect. Additionally, melanoma cells affected eosinophil phenotype upon co-culture. Conclusion: High pre-treatment eosinophil counts in advanced melanoma patients were associated with a significantly improved response to MAPKi. Functionally, eosinophils show potent cytotoxicity towards melanoma cells, which can be reinforced by MAPKi. Further studies are needed to unravel the molecular mechanisms of our observations.},
  language  = {en}
}
@article{TomeiAdamsUccellinietal.2012,
  author    = {Tomei, Sara and Adams, Sharon and Uccellini, Lorenzo and Bedognetti, Davide and De Giorgi, Valeria and Erdenebileg, Narnygerel and Libera Ascierto, Maria and Reinboth, Jennifer and Liu, Qiuzhen and Bevilacqua, Generoso and Wang, Ena and Mazzanti, Chiara and Marincola, Francesco M.},
  title     = {Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population},
  series = {Medical Oncology},
  volume    = {29},
  journal   = {Medical Oncology},
  number    = {5},
  doi       = {dx.doi.org/10.1007/s12032-012-0255-3},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-126834},
  pages     = {3456-3461},
  year      = {2012},
  abstract  = {HRAS belongs to the RAS genes superfamily. RAS genes are important players in several human tumors and the single-nucleotide polymorphism rs12628 has been shown to contribute to the risk of bladder, colon, gastrointestinal, oral, and thyroid carcinoma. We hypothesized that this SNP may affect the risk of cutaneous melanoma as well. HRAS gene contains a polymorphic region (rs112587690), a repeated hexanucleotide -GGGCCT- located in intron 1. Three alleles of this region, P1, P2, and P3, have been identified that contain two, three, and four repeats of the hexanucleotide, respectively. We investigated the clinical impact of these polymorphisms in a case-control study. A total of 141 melanoma patients and 118 healthy donors from the North America Caucasian population were screened for rs12628 and rs112587690 polymorphisms. Genotypes were assessed by capillary sequencing or fragment analysis, respectively, and rs12628 CC and rs112587690 P1P1 genotypes significantly associated with increased melanoma risk (OR = 3.83, p = 0.003; OR = 11.3, p = 0.033, respectively), while rs112587690 P1P3 frequency resulted significantly higher in the control group (OR = 0.5, p = 0.017). These results suggest that rs12628 C homozygosis may be considered a potential risk factor for melanoma development in the North American population possibly through the linkage to rs112587690.},
  language  = {en}
}
@phdthesis{Teutschbein2008,
  author    = {Teutschbein, Janka},
  title     = {Identifizierung und Charakterisierung von Genen und Proteinen in der Xmrk-induzierten Entwicklung von Melanomen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-27516},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2008},
  abstract  = {Melanome stellen die gef{\"a}hrlichste Form von Hautkrebs mit der h{\"o}chsten Mortalit{\"a}tsrate dar. Der Transformation normaler Melanozyten zu malignen Melanomen liegen komplexe molekulare und biochemische Ver{\"a}nderungen zu Grunde. Im Xiphophorus-Melanom-Modell ist die onkogene Rezeptortyrosinkinase "Xiphophorus melanoma receptor kinase" (Xmrk) der alleinige Ausl{\"o}ser der Melanominitiation und -progression. Die Aufkl{\"a}rung der Xmrk-vermittelten Signaltransduktion kann zum besseren Verst{\"a}ndnis von Ereignissen, die auch bei der humanen Melanomentwicklung eine Rolle spielen, beitragen. In der vorliegenden Arbeit wurde mit Hilfe der Microarray-Technologie die Regulation der Genexpression durch Xmrk analysiert. Zu den nach Rezeptoraktivierung am st{\"a}rksten herabregulierten Genen geh{\"o}rten "son of sevenless homolog 1" (Sos1) und "ubiquitin-conjugating enzyme E2I" (Ube2i); stark hochreguliert waren "early growth response 1" (Egr1), "cysteine-rich protein 61" (Cyr61), "dual-specificity phosphatase 4" (Dusp4), "fos-like antigen 1" (Fosl1), "epithelial membrane protein" (Emp1), Osteopontin (Opn), "insulin-like growth factor binding protein 3" (Igfbp3) und "tumor-associated antigen L6" (Taal6). Die f{\"u}r die Regulation dieser Gene verantwortlichen Signalwege wurden durch die Anwendung von niedermolekularen Inhibitoren und siRNA identifiziert, wobei f{\"u}r die SRC-Kinase FYN eine zentrale Bedeutung bei der Xmrk-abh{\"a}ngigen Regulation der Genexpression festgestellt wurde. Dar{\"u}ber hinaus wurde die Expression der Gene in humanen Melanomzelllinien im Vergleich zu normalen humanen Melanozyten untersucht. Als besonders vielversprechende Kandidaten stellten sich dabei DUSP4 und TAAL6 heraus, deren Rolle in der humanen Melanominduktion und -progression Gegenstand zuk{\"u}nftiger Studien sein wird. In einem anderen Ansatz zur Aufkl{\"a}rung des Signalnetzwerkes sollten Zielproteine von Xmrk durch Protein-Protein-Interaktionsstudien mit Hilfe des Split-Ubiquitin-Systems ermittelt werden. Aufgrund ung{\"u}nstiger Expressions- oder Faltungseigenschaften von Xmrk in diesem System war es aber nicht m{\"o}glich, den Rezeptor als K{\"o}derprotein einzusetzen. Das f{\"u}r die Xmrk-vermittelte Melanomentstehung zentrale Protein FYN konnte jedoch als K{\"o}der etabliert und seine Wechselwirkung mit der Tyrosinkinase FAK analysiert werden. Es wurde gezeigt, dass der phosphorylierte Tyrosinrest an Position 397 von FAK f{\"u}r die Interaktion einer N-terminal trunkierten FAK-Variante mit FYN notwendig ist und dass diese Phosphorylierung in Hefe gew{\"a}hrleistet zu sein scheint. Die Suche nach neuen Interaktionspartnern von FYN mittels der Split-Ubiquitin-Technologie k{\"o}nnte Einblicke in weitere FYN-abh{\"a}ngige Ereignisse bieten, die zur Aufkl{\"a}rung seiner zentralen Rolle bei der Tumorentstehung dienen k{\"o}nnte.},
  subject      = {Melanom},
  language  = {de}
}
@article{SchummerSchilling2022,
  author    = {Schummer, Patrick and Schilling, Bastian},
  title     = {How representative are data from global trials on programmed death-1 blockade in melanoma?},
  series = {The British Journal of Dermatology},
  volume    = {187},
  journal   = {The British Journal of Dermatology},
  number    = {3},
  doi       = {10.1111/bjd.21621},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-318406},
  pages     = {283 -- 284},
  year      = {2022},
  language  = {en}
}
@article{SchramaUgurelSuckeretal.2014,
  author    = {Schrama, David and Ugurel, Selma and Sucker, Antje and Ritter, Cathrin and Zapatka, Marc and Schadendorf, Dirk and Becker, J{\"u}rgen Christian},
  title     = {STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients},
  series = {Frontiers in Medicine},
  volume    = {1},
  journal   = {Frontiers in Medicine},
  number    = {47},
  issn      = {2296-858X},
  doi       = {10.3389/fmed.2014.00047},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-120602},
  year      = {2014},
  abstract  = {Interferon alpha (IFNα) is approved for adjuvant treatment of stage III melanoma in Europe and the US. Its clinical efficacy, however, is restricted to a subpopulation of patients while side effects occur in most of treated patients. Thus, the identification of predictive biomarkers would be highly beneficial to improve the benefit to risk ratio. In this regard, STAT3 is important for signaling of the IFNα receptor. Moreover, the STAT3 single-nucleotide polymorphism (SNP) rs4796793 has recently been reported to be associated with IFNα sensitivity in metastatic renal cell carcinoma. To translate this notion to melanoma, we scrutinized the impact of rs4796793 functionally and clinically in this cancer. Interestingly, melanoma cells carrying the minor allele of rs4796793 were the most sensitive to IFNα in vitro. However, we did not detect a correlation between SNP genotype and STAT3 mRNA expression for either melanoma cells or for peripheral blood lymphocytes. Next, we analyzed the impact of rs4796793 on the clinical outcome of 259 stage III melanoma patients of which one-third had received adjuvant IFNα treatment. These analyses did not reveal a significant association between the STAT3 rs4796793 SNP and patients' progression free or overall survival when IFNα treated and untreated patients were compared. In conclusion, STAT3 rs4796793 SNP is no predictive marker for the efficacy of adjuvant IFNα treatment in melanoma patients.},
  language  = {en}
}
@phdthesis{Schrama2004,
  author    = {Schrama, David},
  title     = {T-Zell-priming außerhalb sekund{\"a}rer lymphatischer Gewebe},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-15060},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2004},
  abstract  = {T-Zellimmunantworten werden normalerweise durch folgenden Weg initiiert: unreife dendritische Zellen nehmen Antigen in der Peripherie auf, wandern in die sekund{\"a}ren lymphatischen Organe, wobei sie auf ihrem Weg sowohl reifen als auch das Antigen prozessieren. In den sekund{\"a}ren lymphatischen Organen angekommen, pr{\"a}sentieren sie als reife dendritische Zellen den T-Zellen die Antigene in Form von Peptiden zusammen mit kostimulierenden Molek{\"u}len. Dadurch rufen sie eine spezifische T-Zellantwort hervor. In der vorliegenden Arbeit wurde untersucht, ob nicht Situationen herbeigef{\"u}hrt werden k{\"o}nnen, die ein T-Zell priming außerhalb der sekund{\"a}ren lymphatischen Organe erlauben. Dazu wurden ein murines Modell, bei dem das Zytokin Lymphotoxin-alpha spezifisch am Tumor angereichert wurde, und ein humanes Modell, bei dem reife, antigenbeladene DC intradermal appliziert wurden, untersucht. Im murinen Modell zeigte sich, dass die gerichtete Anreicherung von Lymphotoxin-alpha am Tumor zu dessen Zerst{\"o}rung f{\"u}hrte, welche durch T-Zellen vermittelt wurde, und mit der Induktion eines terti{\"a}ren lymphatischen Gewebes am Tumor assoziiert war. Dieses terti{\"a}re lymphatische Gewebe war durch die Kompartimentalisierung von T- und B-Zellen und der Pr{\"a}senz von high endothelial venules charakterisiert und besaß zudem mit dendritischen Zellen und na{\"i}ven T-Zellen alle Voraussetzungen f{\"u}r ein in loco priming. Dementsprechend konnte in der Folge der gerichteten Lymphotoxin-alpa Therapie im Tumor ein Anstieg am T-Zellinfiltrat, welches sich oligoklonal zusammensetzte, beobachtet werden. In vitro Experimente verdeutlichte die Tumorspezifit{\"a}t der Therapie-induzierten T-Zellantwort, da die T-Zellen auf ein Tumorantigen mit der Aussch{\"u}ttung von Interferon gamma reagierten und die Tumorzellen lysierten. Im humanen Modell wurden Hautbiopsien von Melanompatienten untersucht, denen im Rahmen einer klinischen Studie autologe, in vitro generierte und antigenbeladene DC intradermal appliziert wurden. Die Patienten erlaubten die Entnahme von Hautbiopsien aus den Injektionsstellen f{\"u}r wissenschaftliche Untersuchungen. Eine Induktion bzw. Verst{\"a}rkung einer spezifischen T-Zellantwort durch die Vakzinierung mit antigenbeladenen dendritischen Zellen konnte bereits in zahlreichen Arbeiten und auch in dem in dieser Arbeit untersuchten Patientenkollektiv gezeigt werden. Bei der Analyse der Injektionsstellen zeigt sich, dass ein großer Teil der injizierten dendritischen Zellen in der Vakzinierungsstelle verharren und dass diese unabh{\"a}ngig von einer Beladung mit Antigen zu einer Induktion von high endothelial venules Charakteristika f{\"u}hrte. Waren die dendritischen Zellen mit Antigen beladen, so f{\"u}hrte dies zu einem st{\"a}rkeren T-Zellinfiltrat in den Injektionsstellen, wobei sowohl na{\"i}ve als auch central memory T-Zellen nachgewiesen wurde. Diese Zellen wurden vermutlich durch die {\"U}berexpression der DC CK1 und SDF1 Chemokinen in den Injektionsstellen, die chemotaktisch auf T-Zellen wirken, angezogen. Das Infiltrat in den Injektionsstellen war oligoklonal und wies tumorspezifische T-Zellen auf. Nachdem diese T-Zellklone im Blut der Patienten vor der Vakzinierung nicht nachweisbar waren, m{\"u}ssen sie zumindest in den Injektionsstellen expandiert sein. Interessanterweise konnte einer dieser Klone in Metastasen nachgewiesen werden, die nach der Vakzinierung dem Patienten entfernt wurden. In beiden Modellen wurde also durch die Manipulation des Mikromilieus, d.h. Lymphotoxin-alpa Anreicherung am Tumor bzw. Injektion von reifen dendritischen Zellen in die Haut, Strukturen wie z.B. high endothelial venules induziert, die ein in loco priming erm{\"o}glichen sollten. Dementsprechend riefen diese Ver{\"a}nderungen ein Tumorantigen-spezifisches Infiltrat hervor. Diese Ergebnisse deuten darauf hin, dass T-Zell priming auch außerhalb sekund{\"a}rer lymphatischer Organe erfolgen kann. Prinzipiell scheint also nur der Kontakt von reifen, antigenbeladenen dendritischen Zellen mit den entsprechenden antigenspezifischen, na{\"i}ven T-Zellen entscheiden zu sein. Die M{\"o}glichkeit des in vitro primings bekr{\"a}ftigt diese These. In vivo erfolgt dieses Aufeinandertreffen normalerweise in den sekund{\"a}ren lymphatischen Organen, doch konnte in der vorliegenden Arbeit gezeigt werden, dass Ver{\"a}nderungen des Mikromilieus diesen Kontakt auch in anderen Geweben erm{\"o}glicht.},
  subject      = {T-Lymphozyt},
  language  = {de}
}
@phdthesis{Schmitt2015,
  author    = {Schmitt, Alexandra},
  title     = {Role of Peroxiredoxin 6 in human melanoma},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-111465},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {Peroxiredoxin 6 (PRDX6) is a bifunctional enzyme comprising a peroxidase and a Ca2+-independent phospholipase (iPLA2) activity. This renders the enzyme capable of detoxifying reactive oxygen species (ROS) and of catalyzing the liberation of arachidonic acid (AA) from cellular membranes. Released AA can be further metabolized to bioactive lipids including eicosanoids, which are involved in inflammation, cell growth, differentiation, invasion and proliferation. Human melanoma cells are often characterized by imbalances in both ROS and lipid levels, which can be generated by oncogenic signaling, altered metabolism or UV irradiation. In previous studies, a comparative proteome analysis of the Xiphophorus fish melanoma model revealed a strong upregulation of Prdx6 in benign and malignant lesions compared to healthy skin. As the Xiphophorus melanoma model displays in many respects molecular characteristics that are similar to human melanoma, I investigated the functional role of PRDX6 in human melanoma cells. The first part of the study deals with the regulation of PRDX6 in melanocytes and human melanoma cells. I could demonstrate that the protein level of PRDX6 was strongly enhanced by the induction of the EGFR orthologue Xmrk from the Xiphophorus fish as well as the human EGFR. The upregulation of PRDX6 was further shown to be mediated in a PI3K-dependent and ROS-independent manner. The main part of the thesis comprises the investigation of the functional role of PRDX6 in human melanoma cells as well as the analysis of the underlying mechanism. I could show that knockdown of PRDX6 enhanced the oxidative stress response and led to decreased proliferation of melanoma cells. This cell growth effect was mainly mediated by the iPLA2 activity of PRDX6. Under conditions of strongly enhanced oxidative stress, the peroxidase activity became also important for cellular proliferation. Furthermore, the anti-proliferative effect in cells with lowered PRDX6 levels was the result of reduced cellular AA content and the decrease in the activation of SRC family proteins. Similarly, supplementation with AA led to regeneration of SRC family kinase activity and to an improvement in the reduced proliferation after knockdown of PRDX6. Since AA can be further processed into the prostaglandin PGE2, which has a pro-tumorigenic function in some cancer types, I further examined whether this eicosanoid is involved in the proliferative function of PRDX6. In contrast to AA, PGE2 was not consistently required for melanoma proliferation. In summary, I could demonstrate that PRDX6 plays a major role in AA-dependent lipid signaling in melanoma cells and thereby regulates proliferation. Interestingly, the proliferation relevant iPLA2 activity can be pharmacologically targeted, and melanoma cell growth was clearly blocked by the inhibitor BEL. Thus, I could identify the phospholipase activity of PRDX6 as a new therapeutically interesting target for melanoma treatment.},
  subject      = {Melanom},
  language  = {en}
}
@article{SchmidSchmidtHazuretal.2020,
  author    = {Schmid, Rafael and Schmidt, Sonja K. and Hazur, Jonas and Detsch, Rainer and Maurer, Evelyn and Boccaccini, Aldo R. and Hauptstein, Julia and Teßmar, J{\"o}rg and Blunk, Torsten and Schr{\"u}fer, Stefan and Schubert, Dirk W. and Horch, Raymund E. and Bosserhoff, Anja K. and Arkudas, Andreas and Kengelbach-Weigand, Annika},
  title     = {Comparison of hydrogels for the development of well-defined 3D cancer models of breast cancer and melanoma},
  series = {Cancers},
  volume    = {12},
  journal   = {Cancers},
  number    = {8},
  issn      = {2072-6694},
  doi       = {10.3390/cancers12082320},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-211195},
  year      = {2020},
  abstract  = {Bioprinting offers the opportunity to fabricate precise 3D tumor models to study tumor pathophysiology and progression. However, the choice of the bioink used is important. In this study, cell behavior was studied in three mechanically and biologically different hydrogels (alginate, alginate dialdehyde crosslinked with gelatin (ADA-GEL), and thiol-modified hyaluronan (HA-SH crosslinked with PEGDA)) with cells from breast cancer (MDA-MB-231 and MCF-7) and melanoma (Mel Im and MV3), by analyzing survival, growth, and the amount of metabolically active, living cells via WST-8 labeling. Material characteristics were analyzed by dynamic mechanical analysis. Cell lines revealed significantly increased cell numbers in low-percentage alginate and HA-SH from day 1 to 14, while only Mel Im also revealed an increase in ADA-GEL. MCF-7 showed a preference for 1\% alginate. Melanoma cells tended to proliferate better in ADA-GEL and HA-SH than mammary carcinoma cells. In 1\% alginate, breast cancer cells showed equally good proliferation compared to melanoma cell lines. A smaller area was colonized in high-percentage alginate-based hydrogels. Moreover, 3\% alginate was the stiffest material, and 2.5\% ADA-GEL was the softest material. The other hydrogels were in the same range in between. Therefore, cellular responses were not only stiffness-dependent. With 1\% alginate and HA-SH, we identified matrices that enable proliferation of all tested tumor cell lines while maintaining expected tumor heterogeneity. By adapting hydrogels, differences could be accentuated. This opens up the possibility of understanding and analyzing tumor heterogeneity by biofabrication.},
  language  = {en}
}
@article{RotheBrandenburgHaunetal.2017,
  author    = {Rothe, Hansj{\"o}rg and Brandenburg, Vincent and Haun, Margot and Kollerits, Barbara and Kronenberg, Florian and Ketteler, Markus and Wanner, Christoph},
  title     = {Ecto-5 ' -Nucleotidase CD73 (NT5E), vitamin D receptor and FGF23 gene polymorphisms may play a role in the development of calcific uremic arteriolopathy in dialysis patients - Data from the German Calciphylaxis Registry},
  series = {PLoS One},
  volume    = {12},
  journal   = {PLoS One},
  number    = {2},
  doi       = {10.1371/journal.pone.0172407},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-171817},
  year      = {2017},
  abstract  = {Introduction: Calciphylaxis/calcific uremic arteriolopathy affects mainly end-stage kidney disease patients but is also associated with malignant disorders such as myeloma, melanoma and breast cancer. Genetic risk factors of calciphylaxis have never been studied before. Methods: We investigated 10 target genes using a tagging SNP approach: the genes encoding CD73/ ecto-5'-nucleotidase (purinergic pathway), Matrix Gla protein, Fetuin A, Bone Gla protein, VKORC1 (all related to intrinsic calcification inhibition), calcium-sensing receptor, FGF23, Klotho, vitamin D receptor, stanniocalcin 1 (all related to CKD-MBD). 144 dialysis patients from the German calciphylaxis registry were compared with 370 dialysis patients without history of CUA. Genotyping was performed using iPLEX Gold MassARRAY(Sequenom, San Diego, USA), KASP genotyping chemistry (LGC, Teddington, Middlesex, UK) or sequencing. Statistical analysis comprised logistic regression analysis with adjustment for age and sex. Results: 165 SNPs were finally analyzed and 6 SNPs were associated with higher probability for calciphylaxis (OR>1) in our cohort. Nine SNPs of three genes (CD73, FGF23 and Vitamin D receptor) reached nominal significance (p< 0.05), but did not reach statistical significance after correction for multiple testing. Of the CD73 gene, rs4431401 (OR = 1.71, 95\%CI 1.08-2.17, p = 0.023) and rs9444348 (OR = 1.48, 95\% CI 1.11-1.97, p = 0.008) were associated with a higher probability for CUA. Of the FGF23 and VDR genes, rs7310492, rs11063118, rs13312747 and rs17882106 were associated with a higher probability for CUA. Conclusion: Polymorphisms in the genes encoding CD73, vitamin D receptor and FGF23 may play a role in calciphylaxis development. Although our study is the largest genetic study on calciphylaxis, it is limited by the low sample sizes. It therefore requires replication in other cohorts if available.},
  language  = {en}
}